622 related articles for article (PubMed ID: 8407422)
1. Positron emission tomography with fluorodeoxyglucose to evaluate tumor response and control after radiation therapy.
Chaiken L; Rege S; Hoh C; Choi Y; Jabour B; Juillard G; Hawkins R; Parker R
Int J Radiat Oncol Biol Phys; 1993 Sep; 27(2):455-64. PubMed ID: 8407422
[TBL] [Abstract][Full Text] [Related]
2. Use of positron emission tomography with fluorodeoxyglucose in patients with extracranial head and neck cancers.
Rege S; Maass A; Chaiken L; Hoh CK; Choi Y; Lufkin R; Anzai Y; Juillard G; Maddahi J; Phelps ME
Cancer; 1994 Jun; 73(12):3047-58. PubMed ID: 8200003
[TBL] [Abstract][Full Text] [Related]
3. Positron emission tomography of patients with head and neck carcinoma before and after high dose irradiation.
Greven KM; Williams DW; Keyes JW; McGuirt WF; Watson NE; Randall ME; Raben M; Geisinger KR; Cappellari JO
Cancer; 1994 Aug; 74(4):1355-9. PubMed ID: 8055460
[TBL] [Abstract][Full Text] [Related]
4. Recurrence of head and neck cancer after surgery or irradiation: prospective comparison of 2-deoxy-2-[F-18]fluoro-D-glucose PET and MR imaging diagnoses.
Anzai Y; Carroll WR; Quint DJ; Bradford CR; Minoshima S; Wolf GT; Wahl RL
Radiology; 1996 Jul; 200(1):135-41. PubMed ID: 8657901
[TBL] [Abstract][Full Text] [Related]
5. Prognostic Value of 2-[(18)F] Fluoro-2-deoxy-D-glucose Positron Emission Tomography-Computed Tomography Scan Carried out During and After Radiation Therapy for Head and Neck Cancer Using Visual Therapy Response Interpretation Criteria.
Min M; Lin P; Lee M; Ho Shon I; Lin M; Forstner D; Tieu MT; Chicco A; Bray V; Fowler A
Clin Oncol (R Coll Radiol); 2016 Jun; 28(6):393-401. PubMed ID: 26782837
[TBL] [Abstract][Full Text] [Related]
6. Assessment of axillary lymph node involvement in breast cancer patients with positron emission tomography using radiolabeled 2-(fluorine-18)-fluoro-2-deoxy-D-glucose.
Avril N; Dose J; Jänicke F; Ziegler S; Römer W; Weber W; Herz M; Nathrath W; Graeff H; Schwaiger M
J Natl Cancer Inst; 1996 Sep; 88(17):1204-9. PubMed ID: 8780629
[TBL] [Abstract][Full Text] [Related]
7. Positron emission tomography: an independent indicator of radiocurability in head and neck carcinomas.
Rege S; Safa AA; Chaiken L; Hoh C; Juillard G; Withers HR
Am J Clin Oncol; 2000 Apr; 23(2):164-9. PubMed ID: 10776978
[TBL] [Abstract][Full Text] [Related]
8. Fluorine-18 fluorodeoxyglucose imaging using dual-head coincidence positron emission tomography without attenuation correction in patients with head and neck cancer.
Pai M; Park CH; Suh JH; Koh JH
Clin Nucl Med; 1999 Jul; 24(7):495-500. PubMed ID: 10402001
[TBL] [Abstract][Full Text] [Related]
9. Head and neck cancer: detection of recurrence with PET and 2-[F-18]fluoro-2-deoxy-D-glucose.
Lapela M; Grénman R; Kurki T; Joensuu H; Leskinen S; Lindholm P; Haaparanta M; Ruotsalainen U; Minn H
Radiology; 1995 Oct; 197(1):205-11. PubMed ID: 7568825
[TBL] [Abstract][Full Text] [Related]
10. Correlation between fluorodeoxyglucose hotspots on pretreatment positron emission tomography/CT and preferential sites of local relapse after chemoradiotherapy for head and neck squamous cell carcinoma.
Chaput A; Calais J; Robin P; Thureau S; Bourhis D; Modzelewski R; Schick U; Vera P; Salaün PY; Abgral R
Head Neck; 2017 Jun; 39(6):1155-1165. PubMed ID: 28263422
[TBL] [Abstract][Full Text] [Related]
11. Distinguishing tumor recurrence from irradiation sequelae with positron emission tomography in patients treated for larynx cancer.
Greven KM; Williams DW; Keyes JW; McGuirt WF; Harkness BA; Watson NE; Raben M; Frazier LC; Geisinger KR; Cappellari JO
Int J Radiat Oncol Biol Phys; 1994 Jul; 29(4):841-5. PubMed ID: 8040032
[TBL] [Abstract][Full Text] [Related]
12. Role of positron emission tomography in the management of head and neck cancer in the molecular therapy era.
Garcia C; Flamen P
Curr Opin Oncol; 2008 May; 20(3):275-9. PubMed ID: 18391626
[TBL] [Abstract][Full Text] [Related]
13. Detection of recurrent head and neck squamous cell carcinomas after radiation therapy with 2-18F-fluoro-2-deoxy-D-glucose positron emission tomography.
Farber LA; Benard F; Machtay M; Smith RJ; Weber RS; Weinstein GS; Chalian AA; Alavi A; Rosenthal DI
Laryngoscope; 1999 Jun; 109(6):970-5. PubMed ID: 10369292
[TBL] [Abstract][Full Text] [Related]
14. Usefulness of FDG-PET scan in the assessment of suspected metastatic or recurrent adenocarcinoma of the colon and rectum.
Whiteford MH; Whiteford HM; Yee LF; Ogunbiyi OA; Dehdashti F; Siegel BA; Birnbaum EH; Fleshman JW; Kodner IJ; Read TE
Dis Colon Rectum; 2000 Jun; 43(6):759-67; discussion 767-70. PubMed ID: 10859074
[TBL] [Abstract][Full Text] [Related]
15. Can 3'-Deoxy-3'-((18)F) Fluorothymidine Out Perform 2-Deoxy-2-((18)F) Fluoro-D-Glucose Positron Emission Tomography/Computed Tomography in the Diagnosis of Cervical Lymphadenopathy in Patients With Oral/Head and Neck Cancer?
Schaefferkoetter JD; Carlson ER; Heidel RE
J Oral Maxillofac Surg; 2015 Jul; 73(7):1420-8. PubMed ID: 25869746
[TBL] [Abstract][Full Text] [Related]
16. Occult primary tumors of the head and neck: lack of benefit from positron emission tomography imaging with 2-[F-18]fluoro-2-deoxy-D-glucose.
Greven KM; Keyes JW; Williams DW; McGuirt WF; Joyce WT
Cancer; 1999 Jul; 86(1):114-8. PubMed ID: 10391570
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic accuracy of serial CT/magnetic resonance imaging review vs. positron emission tomography/CT in colorectal cancer patients with suspected and known recurrence.
Potter KC; Husband JE; Houghton SL; Thomas K; Brown G
Dis Colon Rectum; 2009 Feb; 52(2):253-9. PubMed ID: 19279420
[TBL] [Abstract][Full Text] [Related]
18. The current status of positron-emission tomography scanning in the evaluation and follow-up of patients with head and neck cancer.
Kutler DI; Wong RJ; Schoder H; Kraus DH
Curr Opin Otolaryngol Head Neck Surg; 2006 Apr; 14(2):73-81. PubMed ID: 16552262
[TBL] [Abstract][Full Text] [Related]
19. Preoperative diagnostic value of [(18)F] fluorodeoxyglucose positron emission tomography in patients with radioiodine-negative recurrent well-differentiated thyroid carcinoma.
Frilling A; Tecklenborg K; Görges R; Weber F; Clausen M; Broelsch EC
Ann Surg; 2001 Dec; 234(6):804-11. PubMed ID: 11729387
[TBL] [Abstract][Full Text] [Related]
20. 18F-FLT PET does not discriminate between reactive and metastatic lymph nodes in primary head and neck cancer patients.
Troost EG; Vogel WV; Merkx MA; Slootweg PJ; Marres HA; Peeters WJ; Bussink J; van der Kogel AJ; Oyen WJ; Kaanders JH
J Nucl Med; 2007 May; 48(5):726-35. PubMed ID: 17475960
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]